;PMID: 2590949
;source_file_1902.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..40] = [t:0..40]
;1)sentence:[e:46..162] = [t:46..162]
;2)section:[e:166..238] = [t:166..238]
;3)section:[e:242..330] = [t:242..330]
;4)sentence:[e:334..672] = [t:334..672]
;5)sentence:[e:673..793] = [t:673..793]
;6)sentence:[e:794..887] = [t:794..887]
;7)sentence:[e:888..993] = [t:888..993]
;8)sentence:[e:994..1119] = [t:994..1119]
;9)sentence:[e:1120..1237] = [t:1120..1237]
;10)sentence:[e:1238..1372] = [t:1238..1372]
;11)sentence:[e:1373..1538] = [t:1373..1538]
;12)sentence:[e:1539..1634] = [t:1539..1634]
;13)sentence:[e:1635..1688] = [t:1635..1688]
;14)section:[e:1692..1736] = [t:1692..1736]

;section 0 Span:0..40
;Chem Phys Lipids. 1989 Oct;51(2):119-26.
(SEC
  (FRAG (NNP:[0..4] Chem) (NNP:[5..9] Phys) (NNP:[10..16] Lipids) (.:[16..17] .)
        (CD:[18..22] 1989) (CD:[23..28] Oct;5) (CC:[28..30] 1-LRB-)
        (CD:[30..31] 2) (-RRB-:[31..32] -RRB-) (::[32..33] :) (CD:[33..36] 119)
        (::[36..37] -) (CD:[37..39] 26) (.:[39..40] .)))

;sentence 1 Span:46..162
;Effect of natural and structurally modified bile acids on cholesterol 
;metabolizing enzymes in rat liver microsomes.
;[90..100]:substance:"bile acids"
;[104..115]:substance:"cholesterol"
;[130..137]:substance:"enzymes"
(SENT
  (NP-HLN
    (NP (NN:[46..52] Effect))
    (PP (IN:[53..55] of)
      (NP
        (NP (JJ:[56..63] natural)
          (NML-1 (-NONE-:[63..63] *P*)))
        (CC:[64..67] and)
        (NP
          (ADJP (RB:[68..80] structurally) (VBN:[81..89] modified))
          (NML-1 (NN:[90..94] bile) (NNS:[95..100] acids)))))
    (PP (IN:[101..103] on)
      (NP
        (ADJP (NN:[104..115] cholesterol) (VBG:[117..129] metabolizing))
        (NNS:[130..137] enzymes)))
    (PP-LOC (IN:[138..140] in)
      (NP (NN:[141..144] rat) (NN:[145..150] liver) (NNS:[151..161] microsomes)))
    (.:[161..162] .)))

;section 2 Span:166..238
;Crestani M, De Fabiani E, Malavasi B, Cancellieri M, Galli G, Bosisio E.
(SEC
  (FRAG (NNP:[166..174] Crestani) (NNP:[175..177] M,) (NNP:[178..180] De)
        (NNP:[181..188] Fabiani) (NNP:[189..190] E) (,:[190..191] ,)
        (NNP:[192..200] Malavasi) (NNP:[201..202] B) (,:[202..203] ,)
        (NNP:[204..215] Cancellieri) (NNP:[216..218] M,) (NNP:[219..224] Galli)
        (NNP:[225..226] G) (,:[226..227] ,) (NNP:[228..235] Bosisio)
        (NNP:[236..238] E.)))

;section 3 Span:242..330
;Institute of Pharmacological Sciences, Faculty of Pharmacy, University of
;Milan,  Italy.
(SEC
  (FRAG (NNP:[242..251] Institute) (IN:[252..254] of)
        (NNP:[255..270] Pharmacological) (NNPS:[271..279] Sciences)
        (,:[279..280] ,) (NNP:[281..288] Faculty) (IN:[289..291] of)
        (NNP:[292..300] Pharmacy) (,:[300..301] ,) (NNP:[302..312] University)
        (IN:[313..315] of) (NNP:[316..321] Milan) (,:[321..322] ,)
        (NNP:[324..329] Italy) (.:[329..330] .)))

;sentence 4 Span:334..672
;The effect of chenodeoxycholic (CDCA), ursodeoxycholic (UDCA), 
;tauroursodeoxycholic (TUDCA), cholic (CA), ursocholic (UCA) acids, analogues
;of  CDCA and UDCA with a cyclopropyl ring at C22, C23 (cypro-CDCA and
;cypro-UDCA)  and 23-methylursodeoxycholic acid (MUDCA) on cholesterol 7
;alpha-hydroxylase was  studied in rat liver microsomes.
;[348..371]...[458..463]:substance:"chenodeoxycholic (CDCA)"..."acids"
;[373..395]...[458..463]:substance:"ursodeoxycholic (UDCA)"..."acids"
;[398..426]...[458..463]:substance:"tauroursodeoxycholic (TUDCA)"..."acids"
;[428..439]...[458..463]:substance:"cholic (CA)"..."acids"
;[441..463]:substance:"ursocholic (UCA) acids"
;[465..474]:substance:"analogues"
;[479..483]:substance:"CDCA"
;[488..492]:substance:"UDCA"
;[530..540]:substance:"cypro-CDCA"
;[545..555]:substance:"cypro-UDCA"
;[562..591]:substance:"23-methylursodeoxycholic acid"
;[593..598]:substance:"MUDCA"
;[603..634]:cyp450:"cholesterol 7 alpha-hydroxylase"
(SENT
  (S
    (NP-SBJ-2
      (NP (DT:[334..337] The) (NN:[338..344] effect))
      (PP (IN:[345..347] of)
        (NP
          (NP
            (NP
              (NP
                (ADJP
                  (ADJP (JJ:[348..364] chenodeoxycholic))
                  (ADJP (-LRB-:[365..366] -LRB-) (NN:[366..370] CDCA)
                        (-RRB-:[370..371] -RRB-)))
                (NML-1 (-NONE-:[371..371] *P*)))
              (,:[371..372] ,)
              (NP
                (ADJP
                  (ADJP (JJ:[373..388] ursodeoxycholic))
                  (ADJP (-LRB-:[389..390] -LRB-) (NN:[390..394] UDCA)
                        (-RRB-:[394..395] -RRB-)))
                (NML-1 (-NONE-:[395..395] *P*)))
              (,:[395..396] ,)
              (NP
                (ADJP
                  (ADJP (JJ:[398..418] tauroursodeoxycholic))
                  (ADJP (-LRB-:[419..420] -LRB-) (NN:[420..425] TUDCA)
                        (-RRB-:[425..426] -RRB-)))
                (NML-1 (-NONE-:[426..426] *P*)))
              (,:[426..427] ,)
              (NP
                (ADJP
                  (ADJP (JJ:[428..434] cholic))
                  (ADJP (-LRB-:[435..436] -LRB-) (NN:[436..438] CA)
                        (-RRB-:[438..439] -RRB-)))
                (NML-1 (-NONE-:[439..439] *P*)))
              (,:[439..440] ,)
              (NP
                (ADJP
                  (ADJP (JJ:[441..451] ursocholic))
                  (ADJP (-LRB-:[452..453] -LRB-) (NN:[453..456] UCA)
                        (-RRB-:[456..457] -RRB-)))
                (NML-1 (NNS:[458..463] acids))))
            (,:[463..464] ,)
            (NP
              (NP (NNS:[465..474] analogues))
              (PP (IN:[475..477] of)
                (NP (NN:[479..483] CDCA) (CC:[484..487] and)
                    (NN:[488..492] UDCA)))
              (PP (IN:[493..497] with)
                (NP
                  (NP (DT:[498..499] a) (NN:[500..511] cyclopropyl)
                      (NN:[512..516] ring))
                  (PP-LOC (IN:[517..519] at)
                    (NP
                      (NP (NN:[520..523] C22) (,:[523..524] ,)
                          (NN:[525..528] C23))
                      (NP (-LRB-:[529..530] -LRB-) (NN:[530..540] cypro-CDCA)
                          (CC:[541..544] and) (NN:[545..555] cypro-UDCA)
                          (-RRB-:[555..556] -RRB-))))))))
          (CC:[558..561] and)
          (NP
            (NP (JJ:[562..586] 23-methylursodeoxycholic) (NN:[587..591] acid))
            (NP (-LRB-:[592..593] -LRB-) (NN:[593..598] MUDCA)
                (-RRB-:[598..599] -RRB-)))))
      (PP (IN:[600..602] on)
        (NP (NN:[603..614] cholesterol) (CD:[615..616] 7)
            (NN:[617..634] alpha-hydroxylase))))
    (VP (VBD:[635..638] was)
      (VP (VBN:[640..647] studied)
        (NP-2 (-NONE-:[647..647] *))
        (PP-LOC (IN:[648..650] in)
          (NP (NN:[651..654] rat) (NN:[655..660] liver)
              (NNS:[661..671] microsomes)))))
    (.:[671..672] .)))

;sentence 5 Span:673..793
;Cypro-analogues consisted of a mixture of four  diasteroisomers, while MUDCA
;was the racemic mixture of two enantiomers.
;[673..688]:substance:"Cypro-analogues"
;[721..736]:substance:"diasteroisomers"
;[744..749]:substance:"MUDCA"
;[758..773]:substance:"racemic mixture"
;[781..792]:substance:"enantiomers"
(SENT
  (S
    (NP-SBJ (NNS:[673..688] Cypro-analogues))
    (VP (VBD:[689..698] consisted)
      (PP-CLR (IN:[699..701] of)
        (NP
          (NP (DT:[702..703] a) (NN:[704..711] mixture))
          (PP (IN:[712..714] of)
            (NP (CD:[715..719] four) (NNS:[721..736] diasteroisomers)))))
      (,:[736..737] ,)
      (SBAR-ADV (IN:[738..743] while)
        (S
          (NP-SBJ (NN:[744..749] MUDCA))
          (VP (VBD:[750..753] was)
            (NP-PRD
              (NP (DT:[754..757] the)
                 (JJ:[758..765] racemic) (NN:[766..773] mixture))
              (PP (IN:[774..776] of)
                (NP (CD:[777..780] two) (NNS:[781..792] enantiomers))))))))
    (.:[792..793] .)))

;sentence 6 Span:794..887
;Each  steroid was added to liver microsomes at concentrations ranging from 10
;to 200  microM.
;[800..807]:substance:"steroid"
;[869..871]:quantitative-value:"10"
;[875..878]:quantitative-value:"200"
;[880..886]:quantitative-units:"microM"
(SENT
  (S
    (NP-SBJ-2 (DT:[794..798] Each) (NN:[800..807] steroid))
    (VP (VBD:[808..811] was)
      (VP (VBN:[812..817] added)
        (NP-2 (-NONE-:[817..817] *))
        (PP-CLR (TO:[818..820] to)
          (NP (NN:[821..826] liver) (NNS:[827..837] microsomes)))
        (PP-MNR (IN:[838..840] at)
          (NP
            (NP (NNS:[841..855] concentrations))
            (VP (VBG:[856..863] ranging)
              (PP
                (PP (IN:[864..868] from)
                  (NP (CD:[869..871] 10)
                    (NML-1 (-NONE-:[871..871] *RNR*))))
                (PP (TO:[872..874] to)
                  (NP (CD:[875..878] 200)
                    (NML-1 (-NONE-:[878..878] *RNR*))))
                (NML-1 (NN:[880..886] microM))))))))
    (.:[886..887] .)))

;sentence 7 Span:888..993
;With the exception of UCA and CA, all the bile acids inhibited  cholesterol 7
;alpha-hydroxylase activity.
;[910..913]:substance:"UCA"
;[918..920]:substance:"CA"
;[930..940]:substance:"bile acids"
;[952..983]:cyp450:"cholesterol 7 alpha-hydroxylase"
(SENT
  (S
    (PP-1 (IN:[888..892] With)
      (NP
        (NP (DT:[893..896] the) (NN:[897..906] exception))
        (PP (IN:[907..909] of)
          (NP (NN:[910..913] UCA) (CC:[914..917] and) (NN:[918..920] CA)))))
    (,:[920..921] ,)
    (NP-SBJ
      (NP (PDT:[922..925] all) (DT:[926..929] the)
         (NN:[930..934] bile) (NNS:[935..940] acids))
      (PP-1 (-NONE-:[940..940] *T*)))
    (VP (VBD:[941..950] inhibited)
      (NP
        (NML (NN:[952..963] cholesterol) (CD:[964..965] 7)
             (NN:[966..983] alpha-hydroxylase))
        (NN:[984..992] activity)))
    (.:[992..993] .)))

;sentence 8 Span:994..1119
;The inhibition shown by cypro-CDCA and  cypro-UDCA was stronger than that
;observed with the corresponding natural  compounds.
;[1018..1028]:substance:"cypro-CDCA"
;[1034..1044]:substance:"cypro-UDCA"
;[1109..1118]:substance:"compounds"
(SENT
  (S
    (NP-SBJ
      (NP (DT:[994..997] The) (NN:[998..1008] inhibition))
      (VP (VBN:[1009..1014] shown)
        (NP (-NONE-:[1014..1014] *))
        (PP (IN:[1015..1017] by)
          (NP-LGS (NN:[1018..1028] cypro-CDCA) (CC:[1029..1032] and)
                  (NN:[1034..1044] cypro-UDCA)))))
    (VP (VBD:[1045..1048] was)
      (ADJP-PRD
        (ADJP (JJR:[1049..1057] stronger))
        (PP (IN:[1058..1062] than)
          (NP
            (NP (DT:[1063..1067] that))
            (VP (VBN:[1068..1076] observed)
              (NP (-NONE-:[1076..1076] *))
              (PP (IN:[1077..1081] with)
                (NP (DT:[1082..1085] the) (JJ:[1086..1099] corresponding)
                    (JJ:[1100..1107] natural) (NNS:[1109..1118] compounds))))))))
    (.:[1118..1119] .)))

;sentence 9 Span:1120..1237
;22S,23S cypro-UDCA exhibited an inhibitory effect which was more  pronounced
;than that of the diasteroisomer mixture.
;[1120..1138]:substance:"22S,23S cypro-UDCA"
;[1214..1236]:substance:"diasteroisomer mixture"
(SENT
  (S
    (NP-SBJ (NN:[1120..1123] 22S) (,:[1123..1124] ,) (NN:[1124..1127] 23S)
            (NN:[1128..1138] cypro-UDCA))
    (VP (VBD:[1139..1148] exhibited)
      (NP
        (NP (DT:[1149..1151] an) (JJ:[1152..1162] inhibitory)
            (NN:[1163..1169] effect))
        (SBAR
          (WHNP-1 (WDT:[1170..1175] which))
          (S
            (NP-SBJ-1 (-NONE-:[1175..1175] *T*))
            (VP (VBD:[1176..1179] was)
              (ADJP-PRD
                (ADJP (RBR:[1180..1184] more) (JJ:[1186..1196] pronounced))
                (PP (IN:[1197..1201] than)
                  (NP
                    (NP (DT:[1202..1206] that))
                    (PP (IN:[1207..1209] of)
                      (NP (DT:[1210..1213] the)
                         (NN:[1214..1228] diasteroisomer)
                         (NN:[1229..1236] mixture)))))))))))
    (.:[1236..1237] .)))

;sentence 10 Span:1238..1372
;The isomer 22R,23S was less  effective and decreased cholesterol 7
;alpha-hydroxylase activity in a manner  comparable to that of UDCA.
;[1242..1256]:substance:"isomer 22R,23S"
;[1291..1322]:cyp450:"cholesterol 7 alpha-hydroxylase"
;[1367..1371]:substance:"UDCA"
(SENT
  (S
    (NP-SBJ
      (NP (DT:[1238..1241] The) (NN:[1242..1248] isomer))
      (NP (NN:[1249..1252] 22R) (,:[1252..1253] ,) (NN:[1253..1256] 23S)))
    (VP
      (VP (VBD:[1257..1260] was)
        (ADJP-PRD (RBR:[1261..1265] less) (JJ:[1267..1276] effective)))
      (CC:[1277..1280] and)
      (VP (VBD:[1281..1290] decreased)
        (NP
          (NML (NN:[1291..1302] cholesterol) (CD:[1303..1304] 7)
               (NN:[1305..1322] alpha-hydroxylase))
          (NN:[1323..1331] activity))
        (PP-MNR (IN:[1332..1334] in)
          (NP
            (NP (DT:[1335..1336] a) (NN:[1337..1343] manner))
            (ADJP (JJ:[1345..1355] comparable)
              (PP (TO:[1356..1358] to)
                (NP
                  (NP (DT:[1359..1363] that))
                  (PP (IN:[1364..1366] of)
                    (NP (NN:[1367..1371] UDCA))))))))))
    (.:[1371..1372] .)))

;sentence 11 Span:1373..1538
;The effect of CDCA, UDCA and the cyclopropyl  analogues was also tested with
;respect to HMG-CoA reductase and acylCoA  cholesterol acyltransferase (ACAT)
;activities.
;[1387..1391]:substance:"CDCA"
;[1393..1397]:substance:"UDCA"
;[1406..1428]:substance:"cyclopropyl  analogues"
;[1461..1478]:substance:"HMG-CoA reductase"
;[1483..1519]:substance:"acylCoA  cholesterol acyltransferase"
;[1521..1525]:substance:"ACAT"
(SENT
  (S
    (NP-SBJ-2
      (NP (DT:[1373..1376] The) (NN:[1377..1383] effect))
      (PP (IN:[1384..1386] of)
        (NP
          (NP (NN:[1387..1391] CDCA))
          (,:[1391..1392] ,)
          (NP (NN:[1393..1397] UDCA))
          (CC:[1398..1401] and)
          (NP (DT:[1402..1405] the)
             (NN:[1406..1417] cyclopropyl) (NNS:[1419..1428] analogues)))))
    (VP (VBD:[1429..1432] was)
      (ADVP (RB:[1433..1437] also))
      (VP (VBN:[1438..1444] tested)
        (NP-2 (-NONE-:[1444..1444] *))
        (PP (IN:[1445..1449] with)
          (NP
            (NP (NN:[1450..1457] respect))
            (PP (TO:[1458..1460] to)
              (NP
                (NP
                  (NML
                    (NML (NN:[1461..1464] HMG) (HYPH:[1464..1465] -)
                         (NN:[1465..1468] CoA))
                    (NN:[1469..1478] reductase))
                  (NML-1 (-NONE-:[1478..1478] *P*)))
                (CC:[1479..1482] and)
                (NP
                  (NML
                    (NML (NN:[1483..1490] acylCoA) (NN:[1492..1503] cholesterol)
                         (NN:[1504..1519] acyltransferase))
                    (NML (-LRB-:[1520..1521] -LRB-) (NN:[1521..1525] ACAT)
                         (-RRB-:[1525..1526] -RRB-)))
                  (NML-1 (NNS:[1527..1537] activities)))))))))
    (.:[1537..1538] .)))

;sentence 12 Span:1539..1634
;ACAT was stimulated by the isomer  22S,23S cypro-UDCA but not affected by the
;other bile acids.
;[1539..1543]:substance:"ACAT"
;[1566..1572]:substance:"isomer"
;[1574..1592]:substance:"22S,23S cypro-UDCA"
;[1623..1633]:substance:"bile acids"
(SENT
  (S
    (NP-SBJ-1 (NN:[1539..1543] ACAT))
    (VP (VBD:[1544..1547] was)
      (VP
        (VP (VBN:[1548..1558] stimulated)
          (NP-1 (-NONE-:[1558..1558] *))
          (PP (IN:[1559..1561] by)
            (NP-LGS
              (NP (DT:[1562..1565] the) (NN:[1566..1572] isomer))
              (NP (NN:[1574..1581] 22S,23S) (NN:[1582..1592] cypro-UDCA)))))
        (CONJP (CC:[1593..1596] but) (RB:[1597..1600] not))
        (VP (VBN:[1601..1609] affected)
          (NP-1 (-NONE-:[1609..1609] *))
          (PP (IN:[1610..1612] by)
            (NP-LGS (DT:[1613..1616] the) (JJ:[1617..1622] other)
               (NN:[1623..1627] bile) (NNS:[1628..1633] acids))))))
    (.:[1633..1634] .)))

;sentence 13 Span:1635..1688
;No effect was  observed as regards HMG-CoA reductase.
;[1670..1687]:substance:"HMG-CoA reductase"
(SENT
  (S
    (NP-SBJ-1 (DT:[1635..1637] No) (NN:[1638..1644] effect))
    (VP (VBD:[1645..1648] was)
      (VP (VBN:[1650..1658] observed)
        (NP-1 (-NONE-:[1658..1658] *))
        (PP (IN:[1659..1661] as)
          (S-NOM
            (NP-SBJ-1 (-NONE-:[1661..1661] *))
            (VP (VBZ:[1662..1669] regards)
              (NP
                (NML (NN:[1670..1673] HMG) (HYPH:[1673..1674] -)
                     (NN:[1674..1677] CoA))
                (NN:[1678..1687] reductase)))))))
    (.:[1687..1688] .)))

;section 14 Span:1692..1736
;PMID: 2590949 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[1692..1696] PMID) (::[1696..1697] :) (CD:[1698..1705] 2590949)
        (-LRB-:[1706..1707] -LSB-) (NNP:[1707..1713] PubMed)
        (HYPH:[1714..1715] -) (NN:[1716..1723] indexed) (IN:[1724..1727] for)
        (NNP:[1728..1735] MEDLINE) (-RRB-:[1735..1736] -RSB-)))
